| Abstrakt: |
A recent report from Gustave Roussy in Villejuif, France, discusses the landscape of KRAS inhibition in colorectal cancer (CRC) and the emergence of KRAS inhibitors as promising treatment options. The research highlights recent clinical trials evaluating the efficacy of KRAS inhibitors, either alone or in combination with other agents, such as anti-EGFR antibodies. Despite challenges like resistance mechanisms and tumor heterogeneity, the development of KRAS inhibitors represents a significant advance in CRC treatment, offering hope for improved patient outcomes in the future. [Extracted from the article] |
